Dáil Éireann Debate, Tuesday - 27 September 2016
678. Deputy Billy Kelleher asked the Minister for Health if the recent deal on drug costs relates to Irish Pharmaceutical Healthcare Association, IPHA, member companies only; if non-IPHA producers of branded and patented medicines are reducing prices or offering any savings; and if he will make a statement on the matter. [27007/16]
View answerThe new four-year Framework Agreement on the Supply and Pricing of Medicines, signed in July 2016, is an agreement between the State and the Irish Pharmaceutical Healthcare Association (IPHA), and is expected to deliver approximately €600 million in savings over the lifetime of the Agreement.
The principles captured in the Agreement will also be extended to non-IPHA suppliers of branded medicines, leading to additional expected savings in the region of €150 million.
